

May 21, 2001

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Neuropharmacological  
Drug Products, HFD-120  
Attn: Document Control Room  
5600 Fishers Lane  
Rockville, MD 20857-1706

**RESPONSE TO FDA REQUEST**

**Re: NDA 20-592 – Zyprexa (olanzapine)**

Enclosed is additional information regarding our initial response (submitted on July 31, 2000) to your May 1, 2000 letter pertaining to hyperglycemia. The attached "Note to Reviewer" provides a description of the additional data and analyses provided in this submission in order to assist your review.

Please call Dr. Michele Sharp at (317) 277-8382 or me at (317) 277-3799 if there are any questions. Thank you for your continued cooperation and assistance.

Sincerely,

ELI LILLY AND COMPANY



Gregory T. Brophy, Ph.D.  
Director  
U.S. Regulatory Affairs

cc: Mr. Steve Hardeman, RPh (12 desk copies)

ZY 4018 141

Answers That Matter.

**THIS DOCUMENT CONTAINS TRADE SECRETS, OR  
COMMERCIAL OR FINANCIAL INFORMATION,  
PRIVILEGED OR CONFIDENTIAL, DELIVERED  
IN CONFIDENCE AND RELIANCE THAT SUCH  
INFORMATION WILL NOT BE MADE AVAILABLE  
TO THE PUBLIC WITHOUT EXPRESS WRITTEN  
CONSENT OF ELI LILLY AND COMPANY**

ZY 4018 142